Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort
dc.rights.license | open | en_US |
dc.contributor.author | ITALIANO, Antoine | |
dc.contributor.author | BESSEDE, Alban | |
dc.contributor.author | PULIDO, Marina | |
dc.contributor.author | BOMPAS, Emmanuelle | |
dc.contributor.author | PIPERNO-NEUMANN, Sophie | |
dc.contributor.author | CHEVREAU, Christine | |
dc.contributor.author | PENEL, Nicolas | |
dc.contributor.author | BERTUCCI, Francois | |
dc.contributor.author | TOULMONDE, Maud | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | BELLERA, Carine | |
dc.contributor.author | GUEGAN, Jean Philippe | |
dc.contributor.author | REY, C. | |
dc.contributor.author | SAUTES-FRIDMAN, Catherine | |
dc.contributor.author | BOUGOUIN, Antoine | |
dc.contributor.author | CANTAREL, Coralie | |
dc.contributor.author | KIND, Michele | |
dc.contributor.author | SPALATO, M. | |
dc.contributor.author | DADONE-MONTAUDIE, B. | |
dc.contributor.author | LE LOARER, Francois | |
dc.contributor.author | BLAY, Jean Yves | |
dc.contributor.author | FRIDMAN, Wolf H. | |
dc.date.accessioned | 2022-07-12T13:53:45Z | |
dc.date.available | 2022-07-12T13:53:45Z | |
dc.date.issued | 2022-06 | |
dc.identifier.issn | 1546-170X (Electronic) 1078-8956 (Linking) | en_US |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/140447 | |
dc.description.abstractEn | Immune checkpoint inhibitors (ICIs) show limited clinical activity in patients with advanced soft-tissue sarcomas (STSs). Retrospective analysis suggests that intratumoral tertiary lymphoid structures (TLSs) are associated with improved outcome in these patients. PEMBROSARC is a multicohort phase 2 study of pembrolizumab combined with low-dose cyclophosphamide in patients with advanced STS (NCT02406781). The primary endpoint was the 6-month non-progression rate (NPR). Secondary endpoints included objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and safety. The 6-month NPR and ORRs for cohorts in this trial enrolling all comers were previously reported; here, we report the results of a cohort enrolling patients selected based on the presence of TLSs (n = 30). The 6-month NPR was 40% (95% confidence interval (CI), 22.7-59.4), so the primary endpoint was met. The ORR was 30% (95% CI, 14.7-49.4). In comparison, the 6-month NPR and ORR were 4.9% (95% CI, 0.6-16.5) and 2.4% (95% CI, 0.1-12.9), respectively, in the all-comer cohorts. The most frequent toxicities were grade 1 or 2 fatigue, nausea, dysthyroidism, diarrhea and anemia. Exploratory analyses revealed that the abundance of intratumoral plasma cells (PCs) was significantly associated with improved outcome. These results suggest that TLS presence in advanced STS is a potential predictive biomarker to improve patients' selection for pembrolizumab treatment. | |
dc.language.iso | EN | en_US |
dc.title.en | Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort | |
dc.type | Article de revue | en_US |
dc.identifier.doi | 10.1038/s41591-022-01821-3 | en_US |
dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
dc.identifier.pubmed | 35618839 | en_US |
bordeaux.journal | Nature Medicine | en_US |
bordeaux.page | 1199-1206 | en_US |
bordeaux.volume | 28 | en_US |
bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
bordeaux.issue | 6 | en_US |
bordeaux.institution | Université de Bordeaux | en_US |
bordeaux.institution | INSERM | en_US |
bordeaux.team | EPICENE_BPH | en_US |
bordeaux.peerReviewed | oui | en_US |
bordeaux.inpress | non | en_US |
hal.identifier | hal-03721377 | |
hal.version | 1 | |
hal.date.transferred | 2022-07-12T13:53:53Z | |
hal.export | true | |
dc.rights.cc | Pas de Licence CC | en_US |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Nature%20Medicine&rft.date=2022-06&rft.volume=28&rft.issue=6&rft.spage=1199-1206&rft.epage=1199-1206&rft.eissn=1546-170X%20(Electronic)%201078-8956%20(Linking)&rft.issn=1546-170X%20(Electronic)%201078-8956%20(Linking)&rft.au=ITALIANO,%20Antoine&BESSEDE,%20Alban&PULIDO,%20Marina&BOMPAS,%20Emmanuelle&PIPERNO-NEUMANN,%20Sophie&rft.genre=article |
Fichier(s) constituant ce document
Fichiers | Taille | Format | Vue |
---|---|---|---|
Il n'y a pas de fichiers associés à ce document. |